- Professor Sir Stephen Powis suggests weight-loss jabs like Mounjaro could become as common as statins, potentially available in pharmacies, to combat rising obesity rates.
- The NHS is preparing to roll out Mounjaro (tirzepatide) in GP practices, with plans to broaden access through pharmacies and digital services.
- Professor Chris Whitty warns that weight-loss jabs are not a 'get out of jail card' and shouldn't replace public health measures or justify advertising unhealthy foods to children.
- An estimated 1.5 million people in the UK are currently taking weight loss jabs, with around 220,000 expected to benefit from the NHS rollout over the next three years.
- Professor Powis acknowledges potential side effects and the need for proper checks when prescribing these drugs, while also noting that obesity costs the NHS approximately £11.4 billion annually.
IN FULL
